abc131h
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
STAT3d
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Fierce Healthcare2d
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Obesity drugs could help fight opioid addiction, Penn State researchers say
In looking at the profound impact on satiety that GLP-1s have, Penn State College of Medicine Drs. Patrician Grigson and ...
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
Novo Nordisk Shares Rise After FDA Clears Shortage of Anti-Obesity Drugs
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...
Healio2d
FDA removes semaglutide from drug shortage list
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
PMGC submits pre-IND meeting request to FDA for EL-22 in obesity
Northstrive Biosciences has submitted a pre-Investigational New Drug, or pre-IND, meeting request to the FDA for EL-22, a novel myostatin asset ...
USA Today2d
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in December after the FDA found them to no longer be in short supply.